Bentham Science Logo

Contents

Cardiovascular & Hematological Disorders-Drug Targets , Volume 15 - Number 2



Rationale for Development of New Oral Anticoagulants

, 15(2): 89 - 91

Muharrem Akin, Julian Widder, Ibrahim Akin, Michael Brehm and Andreas Schäfer


DOI: 10.2174/1871529X1502151209110044




New Oral Anticoagulants in Coronary Artery Disease

, 15(2): 101 - 105

Michael Behnes, Christian Fastner, Uzair Ansari and Ibrahim Akin


DOI: 10.2174/1871529X1502151209111429



New Oral Anticoagulation after Heart Valve Replacement

, 15(2): 106 - 109

Ibrahim El-Battrawy, Stefan Baumann, Aydin Huseynov and Ibrahim Akin


DOI: 10.2174/1871529X1502151209111735



Novel Oral Anticoagulation During Pulmonary Vein Isolation and Cardioversion

, 15(2): 110 - 114

Christian Fastner, Michael Behnes, Uzair Ansari and Ibrahim Akin


DOI: 10.2174/1871529X1502151209112128



Novel Oral Anticoagulation Laboratory Monitoring, Interaction and Treatment of Complications

, 15(2): 115 - 119

Aydin Huseynov, Stefan Baumann, Ibrahim El-Battrawy and Ibrahim Akin


DOI: 10.2174/1871529X1502151209112437




Validity of Oxygen-Ozone Therapy as Integrated Medication Form in Chronic Inflammatory Diseases

, 15(2): 127 - 138

Velio Bocci, Iacopo Zanardia, Giuseppe Valacchi, Emma Borrelli and Valter Travagli


DOI: 10.2174/1871529X1502151209114642



Apixaban in Venous Thromboembolism in an Era of New Oral Anticoagulants

, 15(2): 139 - 147

Mohit K. Turagam, Poonam Velagapudi, Oluwaseun Adeola, Bhavana Chinnakotla and Martin A. Alpert


DOI: 10.2174/1871529X1502151209120216



Evaluation of a Bone Marrow Dysmyelopoiesis Immunophenotypic Index for the Diagnosis and Prognosis of Myelodysplastic Syndromes

, 15(2): 148 - 161

Evgenia Verigou, Polixeni Lampropoulou, Nikoletta Smyrni, Georgia Kolliopoulou, George Sakellaropoulos, Ioannis Starakis, Panagiotis Zikos, Elena Solomou, Argiris Symeonidis and Marina Karakantza


DOI: 10.2174/1871529X15666150701105822




Webmaster Contact: info@benthamscience.org
Copyright © 2018 Bentham Science